News >

Immunotherapy Continues to Show Promise in TNBC

Jessica Hergert
Published: Thursday, Feb 06, 2020

Rita Nanda, MD, director of the breast oncology program at the University of Chicago

Rita Nanda, MD

Nearly 1 year following the first checkpoint inhibitor approval in advanced triple-negative breast cancer, additional immunotherapeutic agents are poised to enter the field, according to Rita Nanda, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication